Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00789555 · ClinicalTrials.gov registry record · Phase 4
Safety of PATANASE Nasal Spray in Patients With Perennial Allergic Rhinitis
A Phase 4 study, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,260
- Enrollment target
NCT00789555: Completed Phase 4 study, sponsored by Alcon Research.
NCT00789555 is a Phase 4 study that has completed, run by Alcon Research. The registered enrollment target is 1,260 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (143% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00789555, a Phase 4 study, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,260 participants
- Enrollment target
Study Summary
The purpose of this study was to assess local nasal adverse effects, as well as systemic effects, of PATANASE nasal spray when compared with Patanase Vehicle, pH 3.7 and Patanase Vehicle, pH 7.0 in patients with perennial allergic rhinitis (PAR).
Primary Outcome
Percentage of subjects with clinically relevant change from baseline in protocol-specific safety parameters to time of exit, based on the assessment of the investigator, regardless of causality (related or not related) to test article.
Interventions
- DRUG Olopatadine hydrochloride 0.6% nasal spray (PATANASE)
- OTHER Olopatadine nasal spray vehicle, pH 3.7
- OTHER Olopatadine nasal spray vehicle, pH 7.0
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,260 participants |
| Start Date | 2008-11 |
| Est. Completion | 2011-01 |
| Phase | Phase 4 |
What the finished NCT00789555 record still lists
NCT00789555 is an interventional study that assigns participants to a tested intervention. Its 1,260 participants enrollment target places it among the larger protocols in the corpus, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (143% higher).
The record links to 0 conditions, and to 3 interventions - of which Olopatadine hydrochloride 0.6% nasal spray (PATANASE) is the first listed.
NCT00789555 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00789555 about?
NCT00789555 is a clinical study titled "Safety of PATANASE Nasal Spray in Patients With Perennial Allergic Rhinitis". The purpose of this study was to assess local nasal adverse effects, as well as systemic effects, of PATANASE nasal spray when compared with Patanase Vehicle, pH 3.7 and Patanase Vehicle, pH 7.0 in patients with perennial allergic rhinitis (PAR).
What is the current status of trial NCT00789555?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,260 participants. The study started on 2008-11. Estimated completion is 2011-01.
What interventions are being tested in trial NCT00789555?
The interventions under investigation include: Olopatadine hydrochloride 0.6% nasal spray (PATANASE) (DRUG), Olopatadine nasal spray vehicle, pH 3.7 (OTHER), Olopatadine nasal spray vehicle, pH 7.0 (OTHER).
Who is sponsoring clinical trial NCT00789555?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00789555's enrollment target sits among peer trials
1,260 62nd of 2000 higher than 1,939 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06712316 · 1,260 participants · Phase 2
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
- NCT06812273 · 1,260 participants · NA
Mediators and Moderators of Auditory Training
- NCT06931340 · 1,260 participants · Phase 3
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
- NCT06119581 · 1,264 participants · Phase 3
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia